ATLAS: Week 48 Results From Phase III Study of Switching to Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Patients With No Prior Virologic Failure

Source: 2019 Conference on Retroviruses and Opportunistic Infections*
Download Slideset
March 4-7, 2019; Seattle, Washington
Switch to long-acting dual therapy regimen maintains virologic suppression at Week 48.
Format: Microsoft PowerPoint (.ppt)
File Size: 177 KB
Released: March 9, 2019

Acknowledgements

Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings